Wells Fargo’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10
| Closed | -$50 | – | 7730 |
|
|
2024
Q1 | $50 | Hold |
10
| – | – | ﹤0.01% | 6831 |
|
|
2023
Q4 | $69 | Sell |
10
-666
| -99% | -$5.86K | ﹤0.01% | 6858 |
|
|
2023
Q3 | $6.19K | Buy |
676
+66
| +11% | +$1.33K | ﹤0.01% | 5921 |
|
|
2023
Q2 | $12.9K | Buy |
610
+9
| +1% | +$277 | ﹤0.01% | 5842 |
|
|
2023
Q1 | $16.2K | Buy |
601
+201
| +50% | +$9.35K | ﹤0.01% | 5708 |
|
|
2022
Q4 | $14.2K | Sell |
400
-107
| -21% | -$12.9K | ﹤0.01% | 5410 |
|
|
2022
Q3 | $114K | Buy |
507
+18
| +4% | +$4.42K | ﹤0.01% | 4542 |
|
|
2022
Q2 | $93K | Sell |
489
-385
| -44% | -$77.6K | ﹤0.01% | 4684 |
|
|
2022
Q1 | $218K | Sell |
874
-360
| -29% | -$56.9K | ﹤0.01% | 4934 |
|
|
2021
Q4 | $192K | Sell |
1,234
-344
| -22% | -$66.5K | ﹤0.01% | 5289 |
|
|
2021
Q3 | $316K | Buy |
1,578
+1,236
| +361% | +$294K | ﹤0.01% | 4905 |
|
|
2021
Q2 | $87K | Sell |
342
-179
| -34% | -$44.7K | ﹤0.01% | 5345 |
|
|
2021
Q1 | $138K | Sell |
521
-365
| -41% | -$115K | ﹤0.01% | 5330 |
|
|
2020
Q4 | $326K | Buy |
886
+343
| +63% | +$98.4K | ﹤0.01% | 4826 |
|
|
2020
Q3 | $132K | Sell |
543
-150
| -22% | -$46.7K | ﹤0.01% | 5152 |
|
|
2020
Q2 | $199K | Buy |
693
+64
| +10% | +$18.9K | ﹤0.01% | 4917 |
|
|
2020
Q1 | $128K | Sell |
629
-35
| -5% | -$11.2K | ﹤0.01% | 4942 |
|
|
2019
Q4 | $297K | Sell |
664
-33
| -5% | -$11.7K | ﹤0.01% | 4734 |
|
|
2019
Q3 | $214K | Buy |
697
+638
| +1,081% | +$207K | ﹤0.01% | 4927 |
|
|
2019
Q2 | $19K | Sell |
59
-523
| -90% | -$181K | ﹤0.01% | 5798 |
|
|
2019
Q1 | $244K | Sell |
582
-78
| -12% | -$31.3K | ﹤0.01% | 4722 |
|
|
2018
Q4 | $200K | Buy |
660
+539
| +445% | +$174K | ﹤0.01% | 4904 |
|
|
2018
Q3 | $44K | Sell |
121
-4
| -3% | -$1.37K | ﹤0.01% | 5632 |
|
|
2018
Q2 | $46K | Hold |
125
| – | – | ﹤0.01% | 5616 |
|
|
2018
Q1 | $37K | Buy |
125
+17
| +16% | +$5.02K | ﹤0.01% | 5656 |
|
|
2017
Q4 | $45K | Sell |
108
-71
| -40% | -$25.4K | ﹤0.01% | 5597 |
|
|
2017
Q3 | $59K | Buy |
179
+50
| +39% | +$13.6K | ﹤0.01% | 5415 |
|
|
2017
Q2 | $31K | Buy |
129
+4
| +3% | +$909 | ﹤0.01% | 5527 |
|
|
2017
Q1 | $43K | Buy |
125
+25
| +25% | +$8.61K | ﹤0.01% | 5495 |
|
|
2016
Q4 | $35K | Sell |
100
-1
| -1% | -$366 | ﹤0.01% | 5480 |
|
|
2016
Q3 | $41K | Buy |
101
+98
| +3,267% | +$50K | ﹤0.01% | 5381 |
|
|
2016
Q2 | $2K | Sell |
3
-22
| -88% | -$13.4K | ﹤0.01% | 5960 |
|
|
2016
Q1 | $12K | Sell |
25
-12
| -32% | -$5.97K | ﹤0.01% | 5645 |
|
|
2015
Q4 | $25K | Sell |
37
-1
| -3% | -$566 | ﹤0.01% | 5517 |
|
|
2015
Q3 | $18K | Buy |
38
+26
| +217% | +$13.8K | ﹤0.01% | 5575 |
|
|
2015
Q2 | $7K | Sell |
12
-196
| -94% | -$542K | ﹤0.01% | 5924 |
|
|
2015
Q1 | $1.77M | Sell |
208
-3
| -1% | -$26.2K | ﹤0.01% | 3117 |
|
|
2014
Q4 | $1.85M | Buy |
211
+15
| +8% | +$87.1K | ﹤0.01% | 3065 |
|
|
2014
Q3 | $924K | Buy |
196
+194
| +9,700% | +$1.02M | ﹤0.01% | 3524 |
|
|
2014
Q2 | $16K | Buy |
+2
| New | +$10K | ﹤0.01% | 5473 |
|
Other funds holding EIGR
Wells Fargo's EIGR Position: Q2 2024 in Review
Wells Fargo sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 10 shares — an estimated $50 sold.
Wells Fargo first reported a position in EIGR in Q2 2014 and held it in 40 quarters. The position peaked at $1.85M in Q4 2014. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- Wells Fargo reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 10 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $50.
- Wells Fargo first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 40 quarters.
- Wells Fargo's Eiger BioPharmaceuticals, Inc. position peaked at $1.85M in Q4 2014.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.